These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21051930)

  • 1. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.
    Wang C; He X; Zhou B; Li J; Li B; Qian W; Hou S; Wang H; Shi Y; Guo Y
    MAbs; 2011; 3(1):67-75. PubMed ID: 21051930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
    Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
    Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
    Robert F; Ezekiel MP; Spencer SA; Meredith RF; Bonner JA; Khazaeli MB; Saleh MN; Carey D; LoBuglio AF; Wheeler RH; Cooper MR; Waksal HW
    J Clin Oncol; 2001 Jul; 19(13):3234-43. PubMed ID: 11432891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I study of anti-EGFR monoclonal antibody (CMAB009) in patients with advanced cancer].
    He XH; Shi YK; Qin Y; Yang S; Sun Y
    Zhonghua Yi Xue Za Zhi; 2011 Sep; 91(33):2333-5. PubMed ID: 22321747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
    Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
    Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
    Hou MM; Ho CL; Lin HY; Zhu Y; Zhang X
    Invest New Drugs; 2021 Oct; 39(5):1315-1323. PubMed ID: 33713216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
    Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
    J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
    Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
    J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
    Baird RD; Kitzen J; Clarke PA; Planting A; Reade S; Reid A; Welsh L; López Lázaro L; de las Heras B; Judson IR; Kaye SB; Eskens F; Workman P; deBono JS; Verweij J
    Mol Cancer Ther; 2009 Jun; 8(6):1430-7. PubMed ID: 19509256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
    Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
    MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
    Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
    Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
    Garrett CR; Siu LL; El-Khoueiry A; Buter J; Rocha-Lima CM; Marshall J; LoRusso P; Major P; Chemidlin J; Mokliatchouk O; Velasquez L; Hayes W; Feltquate D; Syed S; Ford S; Kollia G; Galbraith S; Nuyten DS
    Br J Cancer; 2011 Jun; 105(1):44-52. PubMed ID: 21629245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.